A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Chen, Shiuan, Ph.D. Bookmark and Share

Shiuan Chen, Ph.D. - Laboratory and Research Focus

Breast Cancer Translational Research
 
Dr. Shiuan Chen was one of the three investigators who originally isolated the full-length human aromatase cDNA clones. Aromatase is an enzyme that converts androgen to estrogen. Aromatase inhibitors (AIs) are important drugs to treat estrogen-dependent breast cancer. Approximately 60% of premenopausal and 75% of postmenopausal breast cancer patients have estrogen-dependent carcinomas.
 
Since aromatase is the enzyme responsible for the synthesis of estrogen, and estrogen can have a major effect in the development of breast cancer, an abnormal expression of aromatase in breast cancer cells and/or surrounding adipose stromal cells may have a significant influence on breast tumor development and growth in cancer patients. Aromatase is expressed at higher levels in human breast cancer tissue than in normal breast tissue, as measured by various biochemical assays. During the last ten years, AIs have been demonstrated to be superior to tamoxifen for the treatment of hormonal dependent breast cancer. While this new generation of aromatase inhibitors is shown to be useful in the treatment of hormonal responsive breast cancer, resistance to such endocrine therapy still develops. Through collaboration with Yate-Ching Yuan, Ph.D., (Bioinformatics), we are carrying out gene expression array experiments on AI-responsive as well as resistant cell lines that have been generated in our laboratory. We plan to identify and functionally confirm the roles of genes involved in resistance.
 
It is hypothesized that these studies will produce valuable molecular information regarding the mechanisms of AI resistance, and the information will help design approaches to reduce resistance and improve the efficacy of AI treatments of breast cancer. Furthermore, our research has led to the identification of a HDAC inhibitor: LBH589 is a selective aromatase expression suppressor and a drug to inhibit the development of AI resistance. After reviewing the results generated from our preclinical studies, we have started working with Joanne Mortimer, M.D., George Somlo, M.D. and Thehang Luu, M.D., (Medical Oncology) in the design of new therapeutic approaches to treat AI resistant breast cancer. Hormone Diagram
 
We are also conducting research to determine how environmental chemicals modulate the activity and expression of aromatase in human tissue. Experiments are being conducted to provide a molecular and mechanistic basis as to how phytochemicals and organochlorine compounds affect estrogen biosynthesis (i.e., aromatase function) in women. Research from Dr. Chen's and other laboratories have revealed that ER, aromatase, and ERRα are key players in breast cancer promotion and in cancer recurrence following endocrine treatment. Furthermore, proof-of-concept studies have revealed that these proteins are targets of endocrine disruptors. Based on these observations, we hypothesize that environmental chemicals will play critical roles in modulating breast cancer through ER, aromatase, and ERRα. The goal of this research is to develop screening assays for identifying and testing chemicals with relevance to known and suspected causes of estrogen-dependent breast cancer. Our collaborators include Richard Yip, Ph.D. (High Throughput Screening Core), Charles Wang, Ph.D. (Functional Genomics Core), Yate-Ching Yuan, Ph.D. (Bioinformatics Core), Christina Teng, Ph.D. (National Institute of Environmental Health Sciences), and Sandra Finestone, Psy.D. (Hope Wellness Center, Costa Mesa, CA).
 
 
Chemoprevention Research Program

Since the summer of 2004, Dr. Chen and 27 other investigators have initiated an effort to develop a chemoprevention research program at City of Hope. Through biweekly meetings, these Beckman researchers and clinicians exchange research information and ideas. Four research areas have recently been chosen to focus on. The immediate goal is to generate preliminary results in these new target areas that will lead to the development of multidiscipline translational chemoprevention research projects at our institution.

Our laboratory has found that grapes, mushrooms and pomegranate contain chemicals that can suppress aromatase activity. Therefore, a diet that includes grapes, mushrooms and pomegranate would be considered preventative against breast cancer. We are purifying and characterizing these natural anti-aromatase chemicals and evaluating their in vivo effects using animal experiments. The active chemicals in grapes have been found to be procyanidin dimers that are present at high concentrations in grape seeds. Melanie Palomares, M.D., (Population Sciences), Jeffrey Weitzel, M.D., (Clinical Cancer Genetics), Tim Synold, Pharm.D., (Experimental Therapeutics) and this laboratory have collaborated and initiated a grape seed extract clinical trial and a mushroom clinical trial based on the chemoprevention studies against breast cancer performed in our laboratory.

Furthermore, we have found that mushrooms contain chemicals that act as inhibitors of steroid 5-alpha reductase. Androgen plays a critical role in prostate cancer development. In the prostate, testosterone (an androgen) is converted to dihydrotestosterone (DHT), an androgen that is even more potent than testosterone. This conversion is catalyzed by the enzyme steroid 5-alpha reductase. An elevation of the steroid 5-alpha reductase activity in the prostate may cause benign prostate hyperplasia (a common problem in older men) and also promote the growth of prostate cancer. Animal experiments have been performed to evaluate the use of these phytochemicals as drugs in the prevention and/or treatment of prostate cancer. One clinical trial designed, based Dr. Chen's findings, is being carried out at City of Hope with Przemyslaw Twardowski, M.D. (Medical Oncology). A recent study in the Chen laboratory has revealed that the intake of mushrooms may reduce the incidence of metabolic diseases such as fatty liver and insulin resistance.

In addition, experiments have been carried out to show that blueberry contains phytochemicals that can suppress the proliferation and migration of triple negative breast cancer in cell culture and animals. Efforts are being made to initiate a blueberry clinical trial at City of Hope.
 
For more information on Dr. Chen, please click here.

Shiuan Chen, Ph.D. Lab Members

Hei (Jason) Chan, B.S.
Graduate Student
626-256-HOPE (4673), Ext. 63056
 
Zhike Chen, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 6506
 
Masaya Kai, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 60562
 
Noriko Kanaya, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 65062
 
Karineh Petrossian, M.S.
Graduate Student
626-256-HOPE (4673), Ext. 65062
 
Yuan-Zhong Wang, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 6305
 
Cynthie Wong , Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 63056
 
Dujin Zhou, Ph.D.
Associate Research Scientist
626-256-HOPE (4673), Ext. 64908
 

Chen, Shiuan, Ph.D.

Shiuan Chen, Ph.D. - Laboratory and Research Focus

Breast Cancer Translational Research
 
Dr. Shiuan Chen was one of the three investigators who originally isolated the full-length human aromatase cDNA clones. Aromatase is an enzyme that converts androgen to estrogen. Aromatase inhibitors (AIs) are important drugs to treat estrogen-dependent breast cancer. Approximately 60% of premenopausal and 75% of postmenopausal breast cancer patients have estrogen-dependent carcinomas.
 
Since aromatase is the enzyme responsible for the synthesis of estrogen, and estrogen can have a major effect in the development of breast cancer, an abnormal expression of aromatase in breast cancer cells and/or surrounding adipose stromal cells may have a significant influence on breast tumor development and growth in cancer patients. Aromatase is expressed at higher levels in human breast cancer tissue than in normal breast tissue, as measured by various biochemical assays. During the last ten years, AIs have been demonstrated to be superior to tamoxifen for the treatment of hormonal dependent breast cancer. While this new generation of aromatase inhibitors is shown to be useful in the treatment of hormonal responsive breast cancer, resistance to such endocrine therapy still develops. Through collaboration with Yate-Ching Yuan, Ph.D., (Bioinformatics), we are carrying out gene expression array experiments on AI-responsive as well as resistant cell lines that have been generated in our laboratory. We plan to identify and functionally confirm the roles of genes involved in resistance.
 
It is hypothesized that these studies will produce valuable molecular information regarding the mechanisms of AI resistance, and the information will help design approaches to reduce resistance and improve the efficacy of AI treatments of breast cancer. Furthermore, our research has led to the identification of a HDAC inhibitor: LBH589 is a selective aromatase expression suppressor and a drug to inhibit the development of AI resistance. After reviewing the results generated from our preclinical studies, we have started working with Joanne Mortimer, M.D., George Somlo, M.D. and Thehang Luu, M.D., (Medical Oncology) in the design of new therapeutic approaches to treat AI resistant breast cancer. Hormone Diagram
 
We are also conducting research to determine how environmental chemicals modulate the activity and expression of aromatase in human tissue. Experiments are being conducted to provide a molecular and mechanistic basis as to how phytochemicals and organochlorine compounds affect estrogen biosynthesis (i.e., aromatase function) in women. Research from Dr. Chen's and other laboratories have revealed that ER, aromatase, and ERRα are key players in breast cancer promotion and in cancer recurrence following endocrine treatment. Furthermore, proof-of-concept studies have revealed that these proteins are targets of endocrine disruptors. Based on these observations, we hypothesize that environmental chemicals will play critical roles in modulating breast cancer through ER, aromatase, and ERRα. The goal of this research is to develop screening assays for identifying and testing chemicals with relevance to known and suspected causes of estrogen-dependent breast cancer. Our collaborators include Richard Yip, Ph.D. (High Throughput Screening Core), Charles Wang, Ph.D. (Functional Genomics Core), Yate-Ching Yuan, Ph.D. (Bioinformatics Core), Christina Teng, Ph.D. (National Institute of Environmental Health Sciences), and Sandra Finestone, Psy.D. (Hope Wellness Center, Costa Mesa, CA).
 
 
Chemoprevention Research Program

Since the summer of 2004, Dr. Chen and 27 other investigators have initiated an effort to develop a chemoprevention research program at City of Hope. Through biweekly meetings, these Beckman researchers and clinicians exchange research information and ideas. Four research areas have recently been chosen to focus on. The immediate goal is to generate preliminary results in these new target areas that will lead to the development of multidiscipline translational chemoprevention research projects at our institution.

Our laboratory has found that grapes, mushrooms and pomegranate contain chemicals that can suppress aromatase activity. Therefore, a diet that includes grapes, mushrooms and pomegranate would be considered preventative against breast cancer. We are purifying and characterizing these natural anti-aromatase chemicals and evaluating their in vivo effects using animal experiments. The active chemicals in grapes have been found to be procyanidin dimers that are present at high concentrations in grape seeds. Melanie Palomares, M.D., (Population Sciences), Jeffrey Weitzel, M.D., (Clinical Cancer Genetics), Tim Synold, Pharm.D., (Experimental Therapeutics) and this laboratory have collaborated and initiated a grape seed extract clinical trial and a mushroom clinical trial based on the chemoprevention studies against breast cancer performed in our laboratory.

Furthermore, we have found that mushrooms contain chemicals that act as inhibitors of steroid 5-alpha reductase. Androgen plays a critical role in prostate cancer development. In the prostate, testosterone (an androgen) is converted to dihydrotestosterone (DHT), an androgen that is even more potent than testosterone. This conversion is catalyzed by the enzyme steroid 5-alpha reductase. An elevation of the steroid 5-alpha reductase activity in the prostate may cause benign prostate hyperplasia (a common problem in older men) and also promote the growth of prostate cancer. Animal experiments have been performed to evaluate the use of these phytochemicals as drugs in the prevention and/or treatment of prostate cancer. One clinical trial designed, based Dr. Chen's findings, is being carried out at City of Hope with Przemyslaw Twardowski, M.D. (Medical Oncology). A recent study in the Chen laboratory has revealed that the intake of mushrooms may reduce the incidence of metabolic diseases such as fatty liver and insulin resistance.

In addition, experiments have been carried out to show that blueberry contains phytochemicals that can suppress the proliferation and migration of triple negative breast cancer in cell culture and animals. Efforts are being made to initiate a blueberry clinical trial at City of Hope.
 
For more information on Dr. Chen, please click here.

Lab Members

Shiuan Chen, Ph.D. Lab Members

Hei (Jason) Chan, B.S.
Graduate Student
626-256-HOPE (4673), Ext. 63056
 
Zhike Chen, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 6506
 
Masaya Kai, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 60562
 
Noriko Kanaya, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 65062
 
Karineh Petrossian, M.S.
Graduate Student
626-256-HOPE (4673), Ext. 65062
 
Yuan-Zhong Wang, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 6305
 
Cynthie Wong , Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 63056
 
Dujin Zhou, Ph.D.
Associate Research Scientist
626-256-HOPE (4673), Ext. 64908
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
NEWS & UPDATES
  • Although chemotherapy can be effective in treating cancer, it can also exact a heavy toll on a patient’s health. One impressive alternative researchers have found is in the form of a vaccine. A type of immunotherapy, one part of the vaccine primes the body to react strongly against a tumor; the second part dire...
  • The breast cancer statistic is attention-getting: One in eight women will be diagnosed with breast cancer during her lifetime. That doesn’t mean that, if you’re one of eight women at a dinner table, one of you is fated to have breast cancer (read more on that breast cancer statistic), but it does mean that the ...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free. In his first post, ...
  • Advanced age tops the list among breast cancer risk factor for women. Not far behind is family history and genetics. Two City of Hope researchers delving deep into these issues recently received important grants to advance their studies. Arti Hurria, M.D., director of the Cancer and Aging Research Program, and ...
  • City of Hope is extending the reach of its lifesaving mission well beyond U.S. borders. To that end, three distinguished City of Hope leaders visited China earlier this year to lay the foundation for the institution’s new International Medicine Program. The program is part of City of Hope’s strategi...
  • A hallmark of cancer is that it doesn’t always limit itself to a primary location. It spreads. Breast cancer and lung cancer in particular are prone to spread, or metastasize, to the brain. Often the brain metastasis isn’t discovered until years after the initial diagnosis, just when patients were beginning to ...
  • Blueberries, cinnamon, baikal scullcap, grape seed extract (and grape skin extract), mushrooms, barberry, pomegranates … all contain compounds with the potential to treat, or prevent, cancer. Scientists at City of Hope have found tantalizing evidence of this potential and are determined to explore it to t...
  • Most women who are treated for breast cancer with a mastectomy do not choose to undergo reconstructive surgery. The reasons for this, according to a recent JAMA Surgery study, vary. Nearly half say they do not want any additional surgery, while nearly 34 percent say breast cancer reconstruction simply isn’t imp...
  • The leading risk factor for breast cancer is simply being a woman. The second top risk factor is getting older. Obviously, these two factors cannot be controlled, which is why all women should be aware of their risk and how to minimize those risks. Many risk factors can be mitigated, and simple changes can lead...
  • All women are at some risk of developing the disease in their lifetimes, but breast cancer, like other cancers, has a disproportionate effect on minorities. Although white women have the highest incidence of breast cancer, African-American women have the highest breast cancer death rates of all racial and ethni...
  • First, the good news: HIV infections have dropped dramatically over the past 30 years. Doctors, researchers and health officials have made great strides in preventing and treating the disease, turning what was once a death sentence into, for some, a chronic condition. Now, the reality check: HIV is still a worl...
  • Screening for breast cancer has dramatically increased the number of cancers found before they cause symptoms – catching the disease when it is most treatable and curable. Mammograms, however, are not infallible. It’s important to conduct self-exams, and know the signs and symptoms that should be checked by a h...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free.   In his previ...
  • In a single day, former professional triathlete Lisa Birk learned she couldn’t have children and that she had breast cancer. “Where do you go from there?” she asks. For Birk, who swims three miles, runs 10 miles and cycles every day, the answer  ultimately was a decision to take control of her cancer care. Afte...
  • More and more people are surviving cancer, thanks to advanced cancer treatments and screening tools. Today there are nearly 14.5 million cancer survivors in the United States. But in up to 20 percent of cancer patients, the disease ultimately spreads to their brain. Each year, nearly 170,000 new cases of brain ...